Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1138091

	registered interest
	date	10/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Analgesics
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of using medicinal cannabis for pain relief.
	tabling member constituency	Brigg and Goole
	tabling member printed	Andrew Percy
	uin	275737
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>An initial impact assessment Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is available at the following link:</p><p> </p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p> </p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. The analysis is limited to the five medical conditions where there is most evidence. These five conditions are multiple sclerosis – pain or muscle spasticity; chemotherapy-induced nausea and vomiting; severe treatment-resistant epilepsy in children - specifically Dravet Syndrome and Lennox-Gastaut Syndrome only; chronic pain in adults and appetite and weight loss associated with HIV/AIDS.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including pain and other disorders unresponsive to existing treatments.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 275738 question first answered 18/07/2019 09:33:54 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3939 label Biography information for Andrew Percy

1138094

	registered interest
	date	10/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Irritable Bowel Syndrome: Cannabis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of using medicinal cannabis to treat Irritable Bowel Syndrome.
	tabling member constituency	Brigg and Goole
	tabling member printed	Andrew Percy
	uin	275738
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>An initial impact assessment Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is available at the following link:</p><p> </p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p> </p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. The analysis is limited to the five medical conditions where there is most evidence. These five conditions are multiple sclerosis – pain or muscle spasticity; chemotherapy-induced nausea and vomiting; severe treatment-resistant epilepsy in children - specifically Dravet Syndrome and Lennox-Gastaut Syndrome only; chronic pain in adults and appetite and weight loss associated with HIV/AIDS.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including pain and other disorders unresponsive to existing treatments.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 275737 question first answered 18/07/2019 09:33:54 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3939 label Biography information for Andrew Percy

1138175

	registered interest
	date	10/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to advertise extra places on the PrEP Impact trial to people who are at risk of HIV.
	tabling member constituency	Bermondsey and Old Southwark
	tabling member printed	Neil Coyle
	uin	275774
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>The pre-exposure prophylaxis (PrEP) Impact Trial is managed by the Trial Sponsor. Recruitment to places in the Trial is managed locally by participating clinics. All information regarding the Trial, including the research clinics which are open to recruitment is available at the following link:</p><p><a href="https://www.prepimpacttrial.org.uk/" target="_blank">https://www.prepimpacttrial.org.uk/</a></p><p>Following funding from NHS England to pay for extra PrEP drug and research costs and the Secretary of State’s announcement on 30 January that the number of places on the PrEP Impact Trial would be doubled to 26,000, expansion of the Trial is now underway across the country.</p><p>In London, boroughs have so far agreed to accept 60% of the total number of additional places available to them, which equates to over 4,000 extra places on the Trial. London local authority commissioners have been asked to confirm that they will accept the remaining 40% of additional places available to them by the end of August at the latest. Participation in the Trial is on a voluntary basis and it is for research clinics and local authorities to decide whether they wish to take part.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/07/2019 09:35:43 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4368 label Biography information for Neil Coyle

1138176

	registered interest
	date	10/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he is having with local authorities in London on increasing access to the PrEP Impact trial.
	tabling member constituency	Bermondsey and Old Southwark
	tabling member printed	Neil Coyle
	uin	275775
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>The pre-exposure prophylaxis (PrEP) Impact Trial is managed by the Trial Sponsor. Recruitment to places in the Trial is managed locally by participating clinics. All information regarding the Trial, including the research clinics which are open to recruitment is available at the following link:</p><p><a href="https://www.prepimpacttrial.org.uk/" target="_blank">https://www.prepimpacttrial.org.uk/</a></p><p>Following funding from NHS England to pay for extra PrEP drug and research costs and the Secretary of State’s announcement on 30 January that the number of places on the PrEP Impact Trial would be doubled to 26,000, expansion of the Trial is now underway across the country.</p><p>In London, boroughs have so far agreed to accept 60% of the total number of additional places available to them, which equates to over 4,000 extra places on the Trial. London local authority commissioners have been asked to confirm that they will accept the remaining 40% of additional places available to them by the end of August at the latest. Participation in the Trial is on a voluntary basis and it is for research clinics and local authorities to decide whether they wish to take part.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/07/2019 09:39:40 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4368 label Biography information for Neil Coyle

1138233

	registered interest
	date	10/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Armed Forces
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps the Government taking to expedite the availability of medicinal cannabis for soldiers suffering from PTSD.
	tabling member constituency	Birkenhead
	tabling member printed	Frank Field
	uin	275687
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law does not restrict the conditions for which these products may be prescribed, interim guidance has been issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists. The use of medicinal cannabis to treat post-traumatic stress disorder (PTSD) is not considered, as the interim guidance focuses only on areas where the evidence base is most developed.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidelines on the prescribing of CBPM, the scope of which is limited to the management of chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy, areas where the evidence base is most developed. The guidelines will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019. This guidance will be routinely updated to take account of emerging evidence.</p><p>An initial impact assessment ‘Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001’ was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is available at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. The analysis is limited to the five medical conditions where there is most evidence. These five conditions are multiple sclerosis – pain or muscle spasticity; chemotherapy-induced nausea and vomiting; severe treatment-resistant epilepsy in children - specifically Dravet Syndrome and Lennox-Gastaut Syndrome only; chronic pain in adults and appetite and weight loss associated with HIV/AIDS.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication and disorders unresponsive to existing treatments.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/07/2019 09:42:32 answering member 4455 label Biography information for Seema Kennedy
	tabling member	478 label Biography information for Lord Field of Birkenhead

1138633

	registered interest
	date	12/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Amazon
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Government's announcement that NHS health information will be made available through Amazon’s Alexa, what steps he plans to take to ensure the privacy of patient data.
	tabling member constituency	Morley and Outwood
	tabling member printed	Andrea Jenkyns
	uin	276567
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>No patient data is being shared with Amazon as part of this agreement. The collaboration with Amazon simply connects people to medical information that is already freely available through the National Health Service website. Use of Amazon Alexa is just an alternative mechanism for accessing that information.</p><p>The agreement signed between the Department and Amazon is clear that none of the data generated through voice search using Alexa will be shared with third parties; that it will not be used for selling products or making product recommendations to Amazon users; nor is it building any form of health profiles on Amazon customers.</p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/07/2019 15:33:33 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4490 label Biography information for Dame Andrea Jenkyns

1138634

	registered interest
	date	12/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgery: Waiting Lists
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking reduce waiting times for routine operations.
	tabling member constituency	Morley and Outwood
	tabling member printed	Andrea Jenkyns
	uin	276568
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>Reducing elective care waiting times continues to be a high priority for the National Health Service. The NHS Long Term Plan sets out the NHS priorities and reiterates the focus on increasing the amount of planned surgery year-on-year, to cut long waits, and reduce the size of hospital waiting lists.</p><p> </p><p>The Long Term Plan also reinforces the NHS commitment to offer choice, including the promise of choice at 26 weeks. This will be delivered as a full rollout over the next year of the planned NHS-managed choice process, which will systematically identify 26-week waiters and contact them to offer choice for treatment at an earlier date.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 18/07/2019 15:48:35 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4490 label Biography information for Dame Andrea Jenkyns

1138810

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Autism and Learning Disability
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS Long-Term Plan implementation framework, what the timeframe is for local areas to produce system plans in relation to services for (a) autistic people and (b) people with learning disabilities.
	tabling member constituency	Worsley and Eccles South
	tabling member printed	Barbara Keeley
	uin	277152
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>Publication of the Implementation Framework begins the process of strategic system planning. System plans for delivery through to 2023/24 are required, with an initial submission in September 2019 and a final submission to follow by mid November 2019. Plans should fully align across the organisations within each system so that they can subsequently be translated into organisational plans for 2020/21, which will be required in early 2020.</p><p> </p><p>The NHS Long Term Plan states that by March 2023/24, inpatient provision will have reduced to less than half of 2015 levels and, for every one million adults, there will be no more than 30 people with a learning disability and/or autism cared for in an inpatient unit. For children and young people, no more than 12 to 15 children with a learning disability, autism or both per million, will be cared for in an inpatient facility.</p><p> </p><p>At a local level, clinical commissioning groups (CCGs) are expected to reduce inappropriate hospitalisation of people with a learning disability, autism or both to meet these targets. The targets are for people for a learning disability, autism or both as a whole and do not differentiate between individual groups of patients (other than by age). The target rates expressed in the Long Term Plan are based on the Office for National Statistics mid-year population estimates for 2017 and translate into different inpatient counts in each CCG dependent on the size of the local population. Areas with larger populations will therefore have higher inpatient targets than those with smaller populations.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 277153 question first answered 18/07/2019 11:24:12 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1588 label Biography information for Barbara Keeley

1138811

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Autism and Learning Disability
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to page 17 of the NHS Long-Term Plan implementation framework, what criteria will be used to calculate the local area share of the required further reduction of inpatient usage and beds for (a) autistic people and (b) people with learning disabilities.
	tabling member constituency	Worsley and Eccles South
	tabling member printed	Barbara Keeley
	uin	277153
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>Publication of the Implementation Framework begins the process of strategic system planning. System plans for delivery through to 2023/24 are required, with an initial submission in September 2019 and a final submission to follow by mid November 2019. Plans should fully align across the organisations within each system so that they can subsequently be translated into organisational plans for 2020/21, which will be required in early 2020.</p><p> </p><p>The NHS Long Term Plan states that by March 2023/24, inpatient provision will have reduced to less than half of 2015 levels and, for every one million adults, there will be no more than 30 people with a learning disability and/or autism cared for in an inpatient unit. For children and young people, no more than 12 to 15 children with a learning disability, autism or both per million, will be cared for in an inpatient facility.</p><p> </p><p>At a local level, clinical commissioning groups (CCGs) are expected to reduce inappropriate hospitalisation of people with a learning disability, autism or both to meet these targets. The targets are for people for a learning disability, autism or both as a whole and do not differentiate between individual groups of patients (other than by age). The target rates expressed in the Long Term Plan are based on the Office for National Statistics mid-year population estimates for 2017 and translate into different inpatient counts in each CCG dependent on the size of the local population. Areas with larger populations will therefore have higher inpatient targets than those with smaller populations.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 277152 question first answered 18/07/2019 11:24:12 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1588 label Biography information for Barbara Keeley

1138812

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Autism and Learning Disability: Community Care and Housing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to page 18 of the NHS Long Term Plan implementation framework, how much additional funding he plans to allocate to support the development of (a) new housing options and (b) suitable accommodation in the community for (i) autistic people and (ii) people with learning disabilities.
	tabling member constituency	Worsley and Eccles South
	tabling member printed	Barbara Keeley
	uin	277154
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>In addition to ongoing capital subsidy by both Ministry of Housing, Communities and Local Government and Department of Health and Social Care, to support the new supply of supported housing, NHS England has committed to invest £100 million of capital funding to support people with a learning disability and autism to live in the community from 2016 to 2021.</p><p> </p><p>Further funding to support housing development relating to the Learning Disability programme from April 2021 will be subject to the capital spending review.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 18/07/2019 11:24:53 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1588 label Biography information for Barbara Keeley